(Press-News.org) MINNEAPOLIS/ST. PAUL (11/19/2024) — Published in Child Psychiatry and Human Development, a research team led by the University of Minnesota Medical School found that Creativity Camp, a two-week arts intervention delivered as a day camp, had a positive impact on mental health and well-being in adolescents with depression.
The idea behind the study is that engaging in the arts offers a pathway for exploring and expanding new ways of thinking, developing insights and sparking self-discovery.
“As a clinician, I am deeply aware of the urgent need for new treatment options for teens with depression. The findings in this report are promising, and I hope they will encourage more research investigating whether and how arts-based interventions like Creativity Camp can help adolescents with depression to recover and thrive,” said Kathryn Cullen, MD, a professor at the U of M Medical School and child and adolescent psychiatrist with M Health Fairview. She is also a member of the Masonic Institute for the Developing Brain.
The research team continues to analyze brain imaging and cognitive data that was collected to evaluate the intervention’s neural and cognitive effects. In future work, they also plan to see if their findings can be replicated using an active comparison group and a larger sample.
Funding was provided by Minnesota Futures through the University of Minnesota Research & Innovation Office, the University of Minnesota Medical School and the University of Minnesota Foundation.
###
About the University of Minnesota Medical School
The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. We acknowledge that the U of M Medical School is located on traditional, ancestral and contemporary lands of the Dakota and the Ojibwe, and scores of other Indigenous people, and we affirm our commitment to tribal communities and their sovereignty as we seek to improve and strengthen our relations with tribal nations. For more information about the U of M Medical School, please visit med.umn.edu.
About the Masonic Institute for the Developing Brain
The Masonic Institute for the Developing Brain (MIDB) is a one-stop clinic, research, and outreach location specializing in children and youth with neurobehavioral conditions. By bringing together University of Minnesota experts in pediatric medicine, research, policy and community supports to understand, prevent, diagnose, and treat neurodevelopmental disorders in early childhood and adolescence, MIDB advances brain health from the earliest stages of development across the lifespan, supporting each person’s journey as a valued community member. Learn more at midb.umn.edu.
END
U of M research finds creativity camp improves adolescent mental health, well-being
2024-11-19
ELSE PRESS RELEASES FROM THIS DATE:
How human brain functional networks emerge and develop during the birth transition
2024-11-19
Brain-imaging data collected from fetuses and infants has revealed a rapid surge in functional connectivity between brain regions on a global scale at birth, possibly reflecting neural processes that support the brain’s ability to adapt to the external world, according to a study published November 19th, in the open-access journal PLOS Biology led by Lanxin Ji and Moriah Thomason from the New York University School of Medicine, USA.
Understanding the sequence and timing of brain functional network ...
Low-dose ketamine shows promise for pain relief in emergency department patients
2024-11-19
Des Plaines, IL — A new study that investigates low-dose ketamine (LDK) as an adjunct to morphine for treating acute pain has been published in the October issue of Academic Emergency Medicine (AEM), the peer-reviewed journal of the Society for Academic Emergency Medicine (SAEM).
The study, titled Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use highlights the potential of low-dose ketamine as a valuable tool in pain management, providing a safe and effective option for emergency medicine physicians managing acute pain.
Pain remains one of the most common and challenging complaints ...
Lifestyle & risk factor changes improved AFib symptoms, not burden, over standard care
2024-11-19
Research Highlights:
A clinical trial with adults who have atrial fibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care (education pamphlets about healthy diet and exercise), followed a lifestyle/risk factor modification program, or took metformin and followed a lifestyle/risk factor modification program.
AFib burden, a measure of how much time a patient experiences atrial arrhythmia, improved during the treatment period — particularly in the standard of care and lifestyle risk factor modification groups.
Lifestyle and risk factor modification was associated ...
Researchers discover new cognitive blueprint for making and breaking habits
2024-11-19
Cognitive neuroscientists in Trinity College Dublin have published new research describing a brand new approach to making habit change achievable and lasting.
This innovative framework has the potential to significantly improve approaches to personal development, as well as the clinical treatment of compulsive disorders (for example obsessive compulsive disorder, addiction, and eating disorders).
The research was led by Dr Eike Buabang, Postdoctoral Research Fellow in the lab of Professor Claire Gillan in the School of Psychology and has been published as a paper, Leveraging ...
In a small international trial, novel oral medication muvalaplin lowered Lp(a)
2024-11-19
Research Highlights:
The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease.
Muvalaplin is a small molecule inhibitor that prevents the bonding of the two protein components that combine to make Lp(a). There are no currently FDA-approved medications to lower Lp(a) levels, though other medications are currently being evaluated in clinical trials. Muvalaplin is the first oral medication developed to lower Lp(a) levels.
Results ...
Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
2024-11-19
WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.
A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care.
A ...
Most Medicare beneficiaries do not compare prescription drug plans – and may be sticking with bad plans
2024-11-19
Every fall, millions of Medicare beneficiaries have the chance to pick a new stand-alone prescription drug plan that may be better suited for them, but most stick with the same plan.
A new study published today in Health Affairs Scholar suggests that 52% of Medicare beneficiaries with stand-alone Part D plans did not switch because they made no plan comparisons at all for 2024. Many of these beneficiaries (41%) also reported not knowing how to switch plans.
“Comparing these Medicare Part D plans is hard, so many beneficiaries just don’t do it. But beneficiaries who don’t compare plans may not notice if they are sticking with more expensive plans or ...
“What Would They Say?” video wins second place in international award for tobacco control advocacy
2024-11-19
DALLAS, Nov. 19, 2024 —“What Would They Say?” – the powerful spoken word poem produced on video by the American Heart Association, which is celebrating 100 years of lifesaving service as the world’s leading voluntary organization focused on heart and brain health, has taken second place in the 4th Annual Anthem Awards winning the Silver Award in the Education, Art & Culture Campaign - Non-Profit Community Engagement category. This international recognition celebrates the Association’s impactful work and historic commitment ...
Black Britons from top backgrounds up to three times more likely to be downwardly mobile
2024-11-19
Even when their parents are lawyers, doctors, or executives, Black Britons are substantially more likely to end up in working class jobs than their White peers, a new study from the University of Kent reveals.
Funded by the Leverhulme Trust, this research shows that Black men from the most advantaged families are three times more likely than White men from similar backgrounds to be in working class jobs beyond age 30. Black women are also twice as likely as White women to experience this kind of downward mobility. This is true even after removing ...
Developing an antibody to combat age-related muscle atrophy
2024-11-19
Fukuoka, Japan—We all age. And while humanity’s life expectancy has increased dramatically in the modern era, we still struggle with the inevitable health issues our bodies face as we get up in the years. For example, the decrease of muscle mass and function, leading to weakness and atrophy. This is a pressing concern in a super-aging society like Japan where—while people live longer—without proper muscle strength, quality of life can be drastically diminished.
In findings that may eventually lead to targeted ...